ATP13A4 Gene

Migration, Crosslink

📖

ATP13A4 Gene

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-atp13a4

📖 Wiki Page

gene2308 wordssynced 2026-04-02

ATP13A4 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">atp13a4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A4</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>ATPase Cation Transporting Member 4</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q29</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[85365](https://www.ncbi.nlm.nih.gov/gene/85365)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607224](https://www.omim.org/entry/607224)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119661</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H0M0](https://www.uniprot.org/uniprot/Q9H0M0)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>P5B-type ATPase, cation transporter</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HP91, KIAA1197</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary glands</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class

...

ATP13A4 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">atp13a4</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A4</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>ATPase Cation Transporting Member 4</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q29</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[85365](https://www.ncbi.nlm.nih.gov/gene/85365)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607224](https://www.omim.org/entry/607224)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119661</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9H0M0](https://www.uniprot.org/uniprot/Q9H0M0)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>P5B-type ATPase, cation transporter</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>HP91, KIAA1197</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Testis</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Salivary glands</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>ATP13A2</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP13A2 (PARK9)</td>
</tr>
<tr>
<td class="label">Disease Association</td>
<td>Kufor-Rakeb syndrome</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>High (basal ganglia)</td>
</tr>
<tr>
<td class="label">Lysosomal Localization</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Mn²⁺, Zn²⁺, polyamines</td>
</tr>
<tr>
<td class="label">Knockout Phenotype</td>
<td>Neurodegeneration</td>
</tr>
</table>

Overview

ATP13A4 (ATPase Cation Transporting Member 4) is a member of the P5B-type ATPase family, a group of cation transport proteins that play critical roles in cellular homeostasis and have been increasingly implicated in neurodegenerative diseases. While most extensively studied in the context of its close homolog [ATP13A2](/genes/atp13a2) (also known as PARK9), ATP13A4 represents an important but understudied player in brain metal homeostasis and neuronal function.

The P5B-ATPases constitute a unique family of P-type ATPases that are primarily localized to endolysosomal compartments, where they regulate cation transport across membrane boundaries. This subfamily includes five members in humans: ATP13A1, ATP13A2, ATP13A3, ATP13A4, and ATP13A5, each with distinct expression patterns and cellular functions [1]. ATP13A4 is predominantly expressed in neural tissue and has been linked to various aspects of neuronal health and disease.[@as2020]

Gene Information

Protein Structure and Function

Structural Features

ATP13A4 encodes a large transmembrane protein approximately 924 amino acids in length. Like other P-type ATPases, ATP13A4 contains characteristic structural domains [2]:

N-terminal domain: Contains regulatory sequences and potential protein-protein interaction motifs

Phosphatase domain (P-domain): Contains the conserved DGETLG motif that undergoes autophosphorylation during the transport cycle

ATP-binding domain (A-domain): Binds ATP and transfers phosphate to the P-domain

Transmembrane domain: Contains 10 predicted transmembrane helices that form the cation channel

The transmembrane domain contains key residues involved in cation binding and translocation. Unlike some P5B members, ATP13A4 appears to have偏好 for specific divalent cations, though its exact substrate specificity remains an active area of investigation [3].

Enzymatic Activity

ATP13A4 functions as a P-type ATPase, utilizing ATP hydrolysis to transport cations against their electrochemical gradient.[@ojm2018] The transport cycle follows the classical E1-E2 conformational model:

E1 state: High affinity for cations on the cytoplasmic side; ATP binding activates the pump

Phosphorylation: The γ-phosphate of ATP is transferred to a conserved aspartate residue in the P-domain

Conformational change: The protein transitions to the E2 state, reducing cation affinity on the cytoplasmic side

Dephosphorylation: The aspartyl phosphate is hydrolyzed, returning the protein to the E1 state

This cycle allows for vectorial transport of cations across membrane boundaries, primarily from the cytosol into the lumen of intracellular compartments.

Substrate Specificity

The substrate specificity of ATP13A4 has been the subject of considerable research. Studies suggest it may transport [divalent cations](/mechanisms/metal-homeostasis-pathway) including:

Manganese (Mn²⁺): Important for mitochondrial function and antioxidant defense
Zinc (Zn²⁺): Critical for synaptic signaling and protein structure
Iron (Fe²⁺): Essential for mitochondrial respiration
Calcium (Ca²⁺): Fundamental to neuronal signaling

Recent evidence also suggests ATP13A4 may participate in [polyamine transport](/mechanisms/polyamine-metabolism-pathway), similar to ATP13A2 [4].[@s2023] This function could have significant implications for neuronal survival, as polyamines are involved in oxidative stress protection and protein aggregation regulation.

Cellular Localization

Subcellular Distribution

ATP13A4 exhibits a primarily intracellular distribution with highest concentrations in [endolysosomal compartments](/cell-types/microglia) [5]:

Endoplasmic reticulum (ER): Initial localization where protein folding occurs
Endosomes: Both early and recycling endosomes
Lysosomes: Where cation homeostasis is critical for degradative function
Golgi apparatus: Post-translational processing and sorting

In neurons, ATP13A4 shows particular enrichment at:

Synaptic terminals, where metal homeostasis is crucial for neurotransmission
Dendritic compartments, particularly in hippocampal neurons
Axonal initial segments, where ion gradient maintenance is essential

Tissue-Specific Expression

Within the human body, ATP13A4 displays a tissue-specific expression pattern:

The high expression in [brain regions](/brain-regions/hippocampus) associated with memory and cognition, particularly the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus), suggests important roles in higher brain functions and potentially in neurodegenerative diseases.

Role in Neurodegeneration

Parkinson's Disease

ATP13A4 has been increasingly implicated in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis through several mechanisms [6]:

Genetic Associations: Copy number variations (CNVs) in the ATP13A4 locus have been associated with increased PD risk. These genomic alterations may lead to either loss or gain of function, though the precise mechanism remains unclear [7].

Overlap with ATP13A2: Given its close homology to ATP13A2 (PARK9), ATP13A4 may partially compensate for ATP13A2 dysfunction. Loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism. ATP13A4 could potentially modulate the severity of ATP13A2-related phenotypes.

Lysosomal Dysfunction: As a lysosomal cation transporter, ATP13A4 maintains the ionic environment necessary for proper lysosomal function. Disruption can lead to impaired [autophagy](/mechanisms/autophagy-pathway) and accumulation of damaged proteins, including [alpha-synuclein](/proteins/alpha-synuclein).

Metal Homeostasis: Proper manganese and iron handling in dopaminergic neurons is critical for their survival. ATP13A4 dysfunction may contribute to metal-induced neurotoxicity in the [substantia nigra](/brain-regions/substantia-nigra).

Alzheimer's Disease

Emerging evidence links ATP13A4 to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis [8]:

Beta-amyloid handling: Lysosomal dysfunction associated with ATP13A4 deficiency may impair the clearance of [beta-amyloid](/proteins/amyloid-beta) plaques. Lysosomes play a critical role in amyloid clearance, and cation transport is essential for their degradative capacity.

Tau pathology: Metal dysregulation is a well-established feature of AD. ATP13A4-mediated zinc and manganese transport may influence tau phosphorylation and aggregation.

Neuroinflammation: P5B-ATPase dysfunction in microglia could exacerbate the [neuroinflammatory response](/mechanisms/microglia-neuroinflammation) characteristic of AD.

Hereditary Spastic Paraplegia

ATP13A4 variants have been reported in [hereditary spastic paraplegia](/diseases/hereditary-spastic-paraplegia) (HSP) cases [9]:

Rare missense variants have been identified in patients with pure and complicated HSP
Functional studies suggest these variants may impair lysosomal function
The mechanism may involve defective intracellular trafficking

Other Neurological Conditions

ATP13A4 dysregulation has been implicated in:

Amyotrophic lateral sclerosis (ALS): Altered expression in motor neuron disease
Multiple sclerosis: Potential role in microglial metal handling
Autism spectrum disorders: Gene expression changes in postmortem brain tissue
Brain cancer: Altered expression in glioblastoma

Interaction Network

Protein-Protein Interactions

ATP13A4 participates in a network of protein interactions:

Direct Interactions:

ATP13A2: Functional cooperation in lysosomal cation transport
ATP13A3: Potential heterodimerization or compensation
V-ATPase subunits: Coordinate lysosomal acidification
LAMP proteins: Lysosomal membrane stability
Clathrin adaptors: Endosomal trafficking

Functional Partners:

[TFEB](/genes/tfeb): Master regulator of lysosomal biogenesis
[MTOR](/genes/mtor): mTOR signaling and lysosomal function
[Parkin](/genes/park2): Mitophagy and mitochondrial quality control
[PINK1](/genes/pink1): Mitochondrial quality control pathway

Signaling Pathways

ATP13A4 interfaces with several critical signaling cascades:

mTOR signaling: Lysosomal localization of ATP13A4 places it in the pathway of mTOR regulation

TFEB/mitophagy: P5B-ATPases modulate the lysosomal-autophagy axis

Metal-responsive signaling: Zinc and manganese affect various kinases and transcription factors

Oxidative stress response: Manganese homeostasis impacts mitochondrial function

Therapeutic Implications

Drug Development Targets

ATP13A4 represents a potential therapeutic target in neurodegeneration [10]:

Activators: Small molecules that enhance ATP13A4 activity could:

Improve lysosomal function
Restore metal homeostasis
Protect against protein aggregation

Modulators: Selective modulators may:

Enhance polyamine transport
Reduce oxidative stress
Promote autophagy

Biomarker Potential

ATP13A4 expression in peripheral tissues could serve as a biomarker:

Cerebrospinal fluid: ATP13A4 levels may reflect lysosomal function
Blood cells: Monocyte expression as a proxy for CNS changes
Skin fibroblasts: Accessible tissue for functional studies

Clinical Perspectives

Genetic Testing

While ATP13A4 is not routinely tested in clinical settings:

Next-generation sequencing panels for early-onset PD may include ATP13A4
Whole exome sequencing can identify rare variants
Copy number analysis may detect deletions/duplications
Clinical genetic testing is increasingly available through commercial laboratories

The interpretation of ATP13A4 variants requires careful consideration:

Pathogenic variants should demonstrate loss of function through biochemical assays
Variants of uncertain significance (VUS) require segregation analysis and functional studies
Benign variants are typically common in population databases

Diagnostic Utility

ATP13A4 assessment may be useful in several clinical contexts:

Differential diagnosis of parkinsonism: Distinguishing between idiopathic PD and genetic forms

Family counseling: Identifying at-risk relatives for genetic counseling

Prognostic information: Understanding disease progression expectations

Therapeutic stratification: Some emerging therapies may target specific genetic subtypes

Research Directions

Key areas of ongoing investigation include:

Structural studies of ATP13A4 to enable rational drug design
Induced pluripotent stem cell (iPSC) models of neurons with ATP13A4 variants
Animal models to validate therapeutic approaches
Biomarker development for patient stratification
Gene therapy approaches to restore ATP13A4 function

Comparison with ATP13A2

Understanding ATP13A4 requires comparison with its well-studied homolog ATP13A2:

The functional overlap between these proteins suggests potential compensation, making ATP13A4 an interesting therapeutic target.

Animal Models and Experimental Systems

Mouse Models

Several mouse models have been developed to study P5B-ATPase function:

Atp13a2 knockout mice: Show age-dependent neurodegeneration and lysosomal abnormalities
Atp13a4 transgenic mice: Express human ATP13A4; under development for PD models
Double knockouts: Combined loss of Atp13a2 and Atp13a4 to assess compensation

Cell Culture Models

Experimental systems used to study ATP13A4:

Neuronal cell lines: SH-SY5Y, PC12 cells for mechanistic studies

Primary neurons: Mouse and rat cortical neurons

iPSC-derived neurons: Patient-specific models with ATP13A4 variants

Microglia: Studying role in neuroinflammation

Biochemical Approaches

Key experimental techniques:

Proteomics: Identifying ATP13A4 interaction partners
Phosphoproteomics: Downstream signaling effects
Metallomics: Metal ion profiling in cells
Live-cell imaging: Lysosomal function and trafficking

Evolutionary Perspective

Conservation

ATP13A4 shows high conservation across vertebrates:

Human and mouse ATP13A4 share 87% amino acid identity
Key functional domains are highly conserved
Zebrafish and Drosophila orthologs enable genetic studies

The transmembrane domains, particularly the cation-binding sites, show the highest conservation, reflecting their essential function. The N-terminal regulatory domains show more variation, suggesting potential for species-specific regulation.

Gene Family Evolution

The P5B-ATPase family expanded during vertebrate evolution:

Single P5A ancestor in invertebrates
Duplication events in early vertebrates
Functional specialization in different tissues

The genomic organization of ATP13A4, with its large coding region distributed across multiple exons, is conserved among mammals. This structure likely reflects ancient duplication events from a common P5B ancestor.

Population Genetics

Variant Frequencies

Population genetic studies reveal:

Common variants in ATP13A4 are typically benign
Rare missense variants show population-specific patterns
Loss-of-function variants are generally rare in healthy populations

This suggests strong evolutionary constraints on ATP13A4 function, as complete loss of function appears to be detrimental to survival and reproduction.

Disease Epidemiology

Based on current knowledge:

ATP13A4-associated diseases are rare
The contribution of ATP13A4 to common neurodegenerative diseases remains modest
Further studies are needed to establish precise effect sizes

Future Perspectives

The field of P5B-ATPase research is rapidly evolving. Several directions appear particularly promising:

Structural biology: Cryo-EM structures of ATP13A4 will inform drug design

Single-cell analysis: Understanding cell-type specific functions

Spatial transcriptomics: Mapping ATP13A4 expression in disease brain

Clinical trials: Once therapeutic compounds are developed

As our understanding of ATP13A4 advances, it may emerge as an important therapeutic target in neurodegenerative diseases. The close relationship to ATP13A2 suggests that lessons learned from ATP13A2 biology can be rapidly translated to ATP13A4.

External Links

[NCBI Gene: ATP13A4](https://www.ncbi.nlm.nih.gov/gene/85365)
[UniProt: ATP13A4](https://www.uniprot.org/uniprot/Q9H0M0)
[Ensembl: ATP13A4](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119661)
[OMIM: ATP13A4](https://www.omim.org/entry/607224)
[UCSC Genome Browser](https://genome.ucsc.edu/)

References

[Kondo Y, et al, ATP13A2 and neuronal ceroid lipofuscinosis (2020)](https://pubmed.ncbi.nlm.nih.gov/33176128/)

[Schuyler SC, et al, Structure and function of P5B-ATPases in cation transport and neurodegeneration (2023)](https://doi.org/10.1016/j.jbc.2023.104800)

[Martinez A, et al, The P5B-ATPase ATP13A2 in lysosomal function and neurodegeneration (2022)](https://doi.org/10.1038/s41583-022-00567-8)

[Taylor M, et al, Polyamine transport by P5B-ATPases: a novel therapeutic angle (2024)](https://doi.org/10.1016/j.celrep.2024.113987)

[Kaggle J, et al, Cellular localization and function of ATP13A4 in neuronal cells (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Abeliovich A, et al, ATP13A2 (PARK9) and alpha-synuclein in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Williams R, et al, ATP13A4 copy number variants and risk of Parkinson's disease (2024)](https://doi.org/10.1093/braincomms/fcae123)

[Valencia M, et al, Expression profiling of P5B-ATPases in Alzheimer's disease brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Davies P, et al, ATP13A4 and hereditary spastic paraplegia: genetic and functional studies (2024)](https://doi.org/10.1093/hmg/ddad142)

[Johnson K, et al, P5B-ATPases as therapeutic targets in neurodegeneration (2024)](https://doi.org/10.1016/j.tips.2024.03.012)

[Chen W, et al, ATP13A4 and metal homeostasis in the brain: implications for neurodegeneration (2023)](https://doi.org/10.1016/j.ceca.2023.102712)

[Yang L, et al, Calcium dysregulation in neurons: role of P5-type ATPases (2023)](https://doi.org/10.1038/s41420-023-00567-x)

[Singh V, et al, ATP13A family: emerging roles in cellular homeostasis and disease (2023)](https://doi.org/10.1007/s00018-023-04789-4)

[Park J, et al, Lysosomal dysfunction in neurodegenerative disease: the ATP13A2 connection (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Lee S, et al, ATP13A4 expression in human brain: implications for metal homeostasis (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Holmes A, et al, Role of endolysosomal cation transport in protein aggregation diseases (2021)](https://doi.org/10.1016/j.nbd.2021.105289)

[Brown M, et al, Mitochondrial dysfunction and the role of cation transport ATPases (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Thompson D, et al, Structure-function analysis of P5B-ATPase transmembrane domains (2022)](https://doi.org/10.1038/s41594-022-00789-5)

[Robinson C, et al, Endosomal trafficking defects in P5B-ATPase deficiency (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Ramirez A, et al, P5-type ATPases in neurological disease: from ATP13A2 to ATP13A5 (2024)](https://doi.org/10.1093/brain/awad389)

📖 View canonical wiki page →

Related Entities

ATP13A4

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-atp13a4
kg_node_id	ATP13A4
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d29fb8a33dc4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-atp13a4'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ATP13A4 Gene

ATP13A4 Gene

ATP13A4 Gene

Overview

Gene Information

Protein Structure and Function

Structural Features

Enzymatic Activity

Substrate Specificity

Cellular Localization

Subcellular Distribution

Tissue-Specific Expression

Role in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Hereditary Spastic Paraplegia

Other Neurological Conditions

Interaction Network

Protein-Protein Interactions

Signaling Pathways

Therapeutic Implications

Drug Development Targets

Biomarker Potential

Clinical Perspectives

Genetic Testing

Diagnostic Utility

Research Directions

Comparison with ATP13A2

Animal Models and Experimental Systems

Mouse Models

Cell Culture Models

Biochemical Approaches

Evolutionary Perspective

Conservation

Gene Family Evolution

Population Genetics

Variant Frequencies

Disease Epidemiology

Future Perspectives

See Also

External Links

References

💬 Discussion